Huons Launches Low-Dose PDRN 'Amotalex Injection 1.5mL'
Optimized Dosage for Local Procedures
Enhancing Utility and Efficiency
Huons has expanded its product lineup by introducing a low-dose polydeoxyribonucleotide (PDRN) injectable.
On July 28, Huons announced the launch of 'Amotalex Injection 1.5mL,' which contains half the volume of the existing 3mL formulation.
Amotalex Injection is an injectable medication whose main ingredient is PDRN extracted from salmon-derived deoxyribonucleic acid (DNA).
Since it is standard practice to discard vial products after opening, using the 1.5mL formulation can minimize drug wastage that previously occurred with the 3mL formulation. Therefore, Amotalex Injection 1.5mL is expected to be used more widely in various medical settings.
Hot Picks Today
If They Fail Next Year, Bonus Drops to 97 Million Won... A Closer Look at Samsung Electronics DS Division’s 600M vs 460M vs 160M Performance Bonuses
- Opening a Bank Account in Korea Is Too Difficult..."Over 150,000 Won in Notarization Fees Just for a Child's Account and Debit Card" [Foreigner K-Finance Status]②
- Meta Begins 10% Workforce Reduction...Zuckerberg: "No Additional Company-Wide Layoffs This Year"
- Room Prices Soar from 60,000 to 760,000 Won and Sudden Cancellations: "We Won't Even Buy Water in Busan" — BTS Fans Outraged
- "Who Is Visiting Japan These Days?" The Once-Crowded Tourist Spots Empty Out... What's Happening?
A Huons representative stated, "The launch of this low-dose PDRN injectable reflects the voices of the medical field," and added, "We will continue to actively consider launching additional formulations that can meet the needs of healthcare professionals."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
!["Please Help Us": How Much Do Those Bowing 90 Degrees These Days Actually Earn? [Data Pick]](https://cwcontent.asiae.co.kr/asiaresize/307/2026052010120870131_1779239528.png)
